CJC-1295 / Ipamorelin

Overview

CJC-1295 / Ipamorelin is a long-acting GH-axis stack built around a GHRH analog and a selective ghrelin-receptor growth-hormone secretagogue. The practical rationale is dual upstream stimulation of the GH/IGF-1 axis. [1][2][3][4]

Because CJC-1295 DAC is designed for longer exposure, the stack is less about frequent pulse timing and more about sustained GH/IGF-1 axis stimulation plus secretagogue signaling. That changes monitoring and side-effect logic. [1][2][7]

Peptides in this stack

Why They're Combined

CJC-1295 is the GHRH-side signal: it stimulates pituitary GHRH receptors and is designed for longer GH/IGF-1 axis exposure. Ipamorelin is the ghrelin/GHS-receptor side: it triggers GH release through a separate receptor pathway with a shorter secretagogue signal. [1][2][3][4]

The stack exists because those signals are complementary, not identical. One component provides sustained GHRH-side stimulation, while the other adds a more direct secretagogue push. The goal is GH-axis support, not proof of a specific body-composition or longevity outcome. [2][3]

How They Work Together

The proposed mechanism is dual upstream stimulation of the GH axis. CJC-1295 acts through the GHRH receptor and can keep GH/IGF-1 signaling elevated over a longer window. Ipamorelin acts as a ghrelin-receptor agonist that produces a shorter secretagogue signal. [1][2][4]

That receptor split is why the stack is discussed for sleep-timed recovery and body-composition support. The same downstream monitoring issues still apply: IGF-1, glucose, edema, numbness or tingling, carpal-tunnel-like symptoms, and anti-doping status. [7][8][9]

What the Evidence Shows

CJC-1295 has human pharmacology evidence showing prolonged GH and IGF-1 stimulation. Ipamorelin has human pharmacokinetic/pharmacodynamic and postoperative-ileus development context. Those are component data, not stack-level outcome evidence. [1][2][4][5]

No controlled human trial establishes that CJC-1295 plus Ipamorelin improves fat loss, muscle gain, sleep quality, recovery, or longevity outcomes compared with either component alone or with approved GH-axis care. The evidence supports receptor logic more than public outcome claims. [7][6]

Typical Protocol

Common CJC-1295 DAC schedules usually use 2 mg per dose, 2-3 times weekly, often before bed. Common Ipamorelin schedules use 200-300 mcg per dose, 1-3 times daily, usually away from food and often before bed or post-workout. [1][4][7]

Many plans use an 8-12 week block before labs and symptoms are reviewed. Because DAC exposure is longer, keep CJC-1295 on fixed weekly days and track IGF-1, fasting glucose, edema, numbness or tingling, sleep quality, blood pressure, and appetite. [2][7]

Important Considerations

This stack refers to the DAC version of CJC-1295, not the short-acting no-DAC form. DAC and no-DAC patterns differ in exposure duration, timing, and practical monitoring. The specific CJC-1295 DAC plus Ipamorelin pairing also has less direct outcome evidence than the broader GHRH-plus-secretagogue mechanism. [1][2]

This is an endocrine stack, so lab and symptom monitoring matter more than with cosmetic or local-repair routines. IGF-1, fasting glucose, edema, numbness or tingling, blood pressure, sleep apnea risk, and cancer history should be part of the review. Tested athletes should treat CJC-1295 and secretagogue combinations as high-risk under anti-doping rules. [7][8][9]

Published research 9 sources